Dr. Adeel Khan
speaker
165 appearances
1 recordings
1 series
first heard Nov 2024
last heard Nov 2024
Dr. Adeel Khan’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Just like, you know, I was an early adopter of Tesla personally. I bought an electric vehicle before anyone else really did. And I was, I was, and, but now it's becoming much more common. And so I think it's going to be the same thing with this, where it's like, okay, there's going to be the early adopters. There's going to be people who are more into this stuff.
And, and it also, I think the way to think about it is if you have the means to do this stuff, you're kind of, you are paving a better way for a future of people because we're at least our company.
You know, we're investing all of our profits back into R&D and trying to push this field forward and trying to really make a difference in regenerative medicine, you know, as opposed to just trying, you know, as opposed to just kind of using it just for profit for yourself type of thing.
So, and that's why I'm, but the only way to push this bill forward is you have to, at the end of the day, do controlled clinical trials because that's the only way you're going to get insurance companies and regulators to buy into this. And that's the long game.
But by being able to offer these offshore treatments that people are willing to pay for and people actually get real results for, they're funding our ability to do the research, which ultimately will be used as justification for regulators to approve it, which I think will take probably seven to 10 years, you know, in terms of getting approvals for specific medical conditions.
Like I think osteoarthritis, for example, is not very far away. We're already getting incredible results with the new cells and hydrogel scaffold, which is kind of, you know, like a jello that protects the stem cells and allows them to stay there so they don't migrate. And the results are already incredible.
And, you know, but just before I came on this call with you, I was talking, we're working with a company that's making custom scaffolds using 3D bioprinting. And that can actually resurface an entire joint. And they've already done that in large animal studies. So the human trials are next. And that's what we're going to do. And so this stuff is not that far away.
Yeah, I mean, look, in Japan, I keep bringing up Japan because they're just so far ahead of us. But in Japan, they actually cover intraarticular stem cell injections. for knee osteoarthritis and cartilage defects. And so, and those are culture expanded stem cells.
And so, the fact that, and the reason I bring Japan up too, because it's not like Columbia or Mexico or Panama, some random country that doesn't really have any sort of developed economy and like rigorous, like Japan has like rigorous standards. Like they're very meticulous with everything.
And so to me, the fact that they're able to approve, not only approve it, but actually have insurance companies reimburse people already just shows you like what's possible. But I think America, there's just so many politics, right? And the politics, unfortunately, affect the ability for us to offer these to patients.
And what I believe is a solution is personally, you know, if our company becomes big enough, I'm going to get some regenerative medicine lobbyists. And you bet you I'm going to get them to start lobbying for us, because I think that's the only way to really get this stuff moving in the U.S.
Well, no, it's not a problem, right? Like I, that company I was just talking about, for example, a 3d bioprinting company, they got, they got a mask national NIH grant.
know for 18 million dollars they're able to do some uh animal studies and some preliminary phase one stuff but now they're hitting a roadblock because obviously they have to they need more money to do more trials and it's so expensive to do clinical trials in the us that you and they can't get any more money from nih so basically they have to go to dc's venture capital or private equity and try to raise money and they're having they can't get it it's like too hard because they're biotech and it's high risk and
Yada, yada, yada.
And so it's really hard for these regenerative medicine companies to fund and find money and to, and honestly, that's, that's actually been my strength is I'm good at finding technology and I have, I have a good networks and I'm able to help like the new cells, for example, Professor Gisela, unfortunately hasn't had the, you know, she, she, she had funding, but then lost her funding because again, politics and,
But I'm able to, you know, help her with that stuff. And I have and then obviously I have marketing and other resources.
And so we can and that's that's kind of my, I guess, vision with this stuff is being able to actually drive this stuff forward by doing the controlled clinical trials of very promising technologies that I believe that, you know, based off the science, I think are going to be a huge part of the future of medicine.
Uh, funny enough, because alternative media is becoming more and more popular. And I think people will demand. that their doctors or people know that, Hey, look, I deserve to have this as an option, you know? And I think that's what it comes down to. Patients have the right to have all their options explored and especially options that are safe and can be just as effective as surgery.
So I think it's, it's, you know, it's unfair to patients to not be able to, or the doctors to not even know anything about this stuff and not be able to have a conversation with their patient about it just because they don't know. Unfortunately, they don't know anything about regenerative medicine. And just because, I mean, you and me didn't learn anything about legitimacy in that school, right?
So there was no education.
Showing 141–160 of 165 · page 8 of 9
← Previous
Next →